Waxman, Ian M.
Yale New Haven Hospital · Memorial Sloan Kettering Cancer Center · Johns Hopkins University · Moffitt Cancer Center · Yale University · Bristol-Myers Squibb (United States) · Dana-Farber Cancer Institute · Sidney Kimmel Comprehensive Cancer Center · Smilow Cancer Hospital
3 papers on CoChat
Most cited papers
- Verified
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine
Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers
Cited by 5,807
- Verified
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 5,519
- Verified
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 1,158
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free